Roland Kolbeck

Company: Spirovant Sciences

Job title: Chief Scientific Officer

Seminars:

Durability and Immunogenicity of Inhaled SP-101, A Novel AAV2.5T Gene Therapy for Cystic Fibrosis 11:30 am

• Understanding the unique durability challenges relating to delivering gene therapies via inhalation to the lung • Exploring a novel AAV capsid (AAV2.5T) for inhaled delivery of a CFTR minigene (hCFTRdR) for the treatment of Cystic Fibrosis • Assessing data to understand the durability of hCFTRdR transgene expression and associated immunogenicityRead more

day: Day One AM